Bone marrow transplantation for lymphoma CR1

Current Opinion in Oncology

Volumn 17, Issue 2, 2005, Pages 99-105

  Tarella, Corrado ^a   Gianni, Alessandro M ^b  

^a Dipto di Med e Oncol Sperimentale Div Universitaria di Ematologia   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Bone marrow autograft; In vivo purging; Non Hodgkin lymphoma; Peripheral blood progenitor cells; Radioimmunotherapy; Therapy

Indexed keywords

ALPHA INTERFERON; CARMUSTINE; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; RITUXIMAB; VINCRISTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; HIGH RISK PATIENT; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW;

BONE MARROW TRANSPLANTATION; HUMANS; LYMPHOMA;

EID: 17144411519     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000152976.47551.d3     Document Type: Review

References (49)

1. Salles G, Coiffier B. Autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Baillieres Best Pract Res Clin Haematol 1999; 12:151-169.
2. Rohatiner AZS, Johnson PWM, Price CGA, et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 1994; 12:1177-1184.
3. Philip T, Guglielmi C, Hagenbeck A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333:1540-1545.
4. Shipp MA, Abeloff MD, Antman KH, et al. International Consensus Conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphoma: report of the jury. J Clin Oncol 1999; 17:423-429.
5. Hunault-Berger M, Ifrah N, Solal-Celigny P. Intensive therapies in follicular non-Hodgkin lymphomas. Blood 2002; 100:1141-1152.
6. Gianni AM, Siena S, Bregni M, et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haematopoietic stem cells for autotransplantation. Lancet 1989; 2:580-585.
7. Schmitz N, Linch DC, Dreger P, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients. Lancet 1996; 347:353-357.
8. Hartmann O, Le Corroller AG, Blaise D, et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphoma: hematologic recovery and cost. Ann Intern Med 1997; 126:600-607.
9. Gianni AM, Bregni M, Siena S, et al. Rapid and complete hemopoietic reconstitution following combined transplantation of autologous blood and bone marrow cells: a changing role for high dose chemo-radiotherapy? Hematol Oncol 1989; 7:139-148.
10. Bosly A, Sonnet A, Salles G, et al. Superiority of late over early intensification in relapsing/refractory aggressive non-Hodgkin's lymphoma: a randomized study from the GELA:LNH RP 93. Blood 1997; 90(suppl 1):S594.
11. Gisselbrecht C, Lepage E, Molina T, et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002; 20:2472-2479.
12. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001; 97:616-623.
13. Tarella C, Cuttica A, Vitolo U, et al. High-dose sequential chemotherapy and peripheral blood progenitor cell (PBPC) autografting in refractory/relapsed Hodgkin's lymphoma: s multicenter study of the Intergruppo Italiano Linfomi (IiI) showing prolonged disease-free survival in patients treated at first relapse. Cancer 2003; 97:2748-275g.
14. Gianni AM, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336:1290-1297.
15. Strehl J, Mey U, Glasmacher A, et al. High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis. Haematologica 2003; 88:1304-1315. This publication reports the largest prospective randomized trials comparing ASCT with conventional chemotherapy performed in the past decade for DLCL patients at diagnosis
16. Cuttica A, Zallio F, Ladetto M, et al. Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting: evidence of marked differences in outcome between patients with age-adjusted International Prognostic Index scores 2 and 3. Cancer 2003; 98:983-992.
17. Milpied N, Deconinck E, Gaillard F, et al. Groupe Ouest-Est des Leucemies et des Autres Maladies du Sang. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004; 350:1287-1295. This is well-sized randomized trial shows the superiority of ASCT over conventional chemotherapy as first-line treatment for intermediate/high- risk (aalPI 2) DLCL patients.
18. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329:987-994.
19. Lister TA, Who should receive myeloablative therapy for lymphoma? N Engl J Med 2004; 350:1277-1278.
20. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235-242.
21. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL Blood 2004; 104:626-633.
22. Freedman AS, Gribben JG, Neuberg D, et al. High-dose therapy and autologous bone marrow transplantation in patients with follicufar lymphoma during first remission. Blood 1996; 88:2780-2786.
23. Tarella C, Caracciolo D, Corradini P, et al. Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft. Leukemia 2000; 14:740-747.
24. Horning SJ, Negrin RS, Hoppe RT, et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood 2001; 97:404-409.
25. Cohen Y, Solal-Celigny P, Polliack A. Rituximab therapy for follicular lymphoma: a comprehensive review of its efficacy as primary treatment, treatment for relapsed disease, re-treatment and maintenance. Haematologica 2003; 88:811-823. (Review)
26. Corradini P, Ladetto M, Zallio F, et al. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol 2004; 22:1460-1468. This study of a relatively large series of indolent NHL with a prolonged follow-up time shows that the up-front use of intensive chemotherapy with ASCT allows prolonged clinical and molecular remission in a sizable proportion of FCL patients.
27. Ladetto M, Corradini P, Vallet S, et al. High rates of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (Gitmo). Blood 2002; 100:1559-1565.
28. Lenz G, Dreyling M, Schiegnitz E, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Blood 2004 [Epub ahead of print].
29. Voso MT, Pantel G, Weis M, et al. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. Br J Haematol 2000; 109:729-735.
30. Magni M, Di Nicola M, Devizzi L, et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96:864-869.
31. Flinn IW, O'Donnell PV, Goodrich A, et al. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2000; 6:628-632.
32. Belhadj K, Delfau-Larue MH, Elgnaoui T, et al. Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study. Ann Oncol 2004; 15:504-510.
33. Ladetto M, Zallio F, Vallet S, et al. Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. Leukemia 2001; 15:1941-1949.
34. Gianni AM, Magni M, Martelli M, et al. Long-term remission in mantle-cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 2003; 102:749-755.
35. Ladetto M, Ricca I, Benedetti F, et al. Multicenter prospective randomized GITMO trial comparing high-dose sequential chemotherapy and CHOP both supplemented with rituximab as frontline therapy for high-risk follicular lymphoma patients: an interim analysis. Blood 2002; 100:4769a.
36. Horwitz SM, Negrin RS, Blume KG, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004; 103:777-783.
37. Press OW, Eary JF, Gooley T, et al. A phase I/II trial of iodine-131 -tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000; 96:2934-2942.
38. Gopal AK, Gooley TA, Maloney DG, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood 2003; 102:2351-2357. This study of a series of 20 NHL patients demonstrates both the feasibility and the efficacy of radioimmunotherapy delivered at a high dose as a conditioning regimen before autograft
39. Lenz G, Dreyling M, Hiddemann W. Mantle cell lymphoma: established therapeutic options and future directions. Ann Hematol 2004; 83:71-77.
40. Hess G, Rohr T, Huber C, et al. Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma. Bone Marrow Transplant 2003; 31:775-782.
41. Andersen NS, Pedersen L, Elonen E, et al. Nordic Lymphoma Group, primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant. Eur J Haematol 2003; 71:73-80.
42. Khouri IF, Saliba RM, Okoroji GJ, et al. Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score. Cancer 2003; 98:2630-2635.
43. Mangel J, Leitch HA, Connors JM, et al. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. Ann Oncol 2004; 15:283-290. This matched-pair analysis shows a statistically significant better PFS and a trend towards a better OS in MCL patients treated up front with rituximab-ASCT than with conventionally treated historical control participants.
44. Khouri IF, Lee M-S, Saliba RM, et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 2003; 21:4407-4412. This paper reports the extremely favorable outcome in 18 patients with advanced/recurrent MCL after nonablative allogeneic transplantation.
45. Abrey LE, Moskowitz CH, Mason WP, et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 2003; 21:4151-4156.
46. Schetelig J, Fetscher S, Reichle A, et al. Long-term disease-free sur2vival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica 2003; 88:1272-1278.
47. Corradini P, Dodero A, Zallio F, et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004; 22:2172-2176. This paper reports the unexpectedly favorable outcome in 17 patients with advanced/recurrent T cell NHL, 8 of them previously treated with ASCT, after non-ablative allogeneic transplantation.
48. Escalon MP, Champlin RE, Saliba RM, et al. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 2004; 22:2419-2423. This paper reports the extremely favorable outcome in 10 patients treated with nonablative allogeneic transplantation for NHL progressing after ASCT.
49. Re A, Cattaneo C, Michieli M, et al. High-dose therapy and autologous peripheral-blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy. J Clin Oncol 2003; 21:4423-4427. The study describes the successful use of an ASCT program in 16 consecutive patients with resistant/relapsed HIV-associated lymphoma.